This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / Minerva Neurosciences forms SAB for...
Business board formation

Minerva Neurosciences forms SAB for Roluperidone

Analysis based on 6 articles · First reported Jun 01, 2026 · Last updated Jun 01, 2026

Sentiment
20
Attention
3
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The formation of the Scientific Advisory Board by Minerva Neurosciences is a positive development, as it brings expert guidance to the development of Roluperidone, potentially increasing the likelihood of its successful approval and commercialization. This could lead to a positive impact on Minerva Neurosciences' stock price and future revenue prospects.

Biotechnology Pharmaceuticals
Event Summary

Minerva Neurosciences, a clinical-stage biopharmaceutical company, announced the formation of its Scientific Advisory Board (SAB). This board comprises distinguished experts in psychiatry and neuroscience, including Michael Davidson, Phil Harvey, Oliver Howes, Inder Kaul, Brian Kirkpatrick, Remy Luthringer, Avi Reichenberg, and Greg Strauss. The SAB's primary role is to advise on the research and development activities of Minerva Neurosciences, particularly focusing on the ongoing Phase 3 confirmatory clinical trial (NCT07565428; MIN-101C19) of Roluperidone. Roluperidone is an investigational drug for the treatment of negative symptoms of schizophrenia, an area with significant unmet medical need in the United States. The trial aims to confirm the drug's effect on primary negative symptoms and evaluate longer-term relapse rates. Topline data from the 12-week Phase A portion of the trial are expected in the second half of 2027. The formation of the SAB fulfills a commitment made during Minerva Neurosciences' PIPE financing in October 2025.

Entities Involved
stock
Minerva Neurosciences
Minerva Neurosciences formed a Scientific Advisory Board to guide the development of roluperidone and its broader R&D strategy, which is expected to enhance the scientific rigor and clinical expertise applied to its drug development programs.
Importance 100.0 Sentiment 20.0
oth
Roluperidone
Roluperidone is an investigational drug being evaluated in a Phase 3 clinical trial for negative symptoms of schizophrenia, and its development will be guided by the newly formed Scientific Advisory Board of Minerva Neurosciences.
Importance 90.0 Sentiment 20.0
per
Remy Luthringer
Remy Luthringer, CEO of Minerva Neurosciences, announced the formation of the Scientific Advisory Board and emphasized its importance for the development of Roluperidone and the company's pipeline.
Importance 70.0 Sentiment 10.0
per
Michael Davidson
Michael Davidson, Chief Medical Officer of Minerva Neurosciences, is a member of the newly formed Scientific Advisory Board.
Importance 50.0 Sentiment 10.0
per
Inder Kaul
Inder Kaul, Chief Medical Officer of Draig Therapeutics and a board member of Minerva Neurosciences, is part of the Scientific Advisory Board.
Importance 50.0 Sentiment 10.0
per
Phil Harvey
Phil Harvey, a Professor of Psychiatry and Behavioral Sciences at University of Miami, is a member of the Scientific Advisory Board.
Importance 40.0 Sentiment 10.0
per
Oliver Howes
Oliver Howes, a Professor of Molecular Psychiatry at King s College London, is a member of the Scientific Advisory Board.
Importance 40.0 Sentiment 10.0
per
Brian Kirkpatrick
Brian Kirkpatrick, a Professor of Psychiatry at University of Arkansas for Medical Sciences, is a member of the Scientific Advisory Board.
Importance 40.0 Sentiment 10.0
per
Avi Reichenberg
Avi Reichenberg, a Professor of Psychiatry and Preventive Medicine at Icahn School of Medicine at Mount Sinai, is a member of the Scientific Advisory Board.
Importance 40.0 Sentiment 10.0
per
Greg Strauss
Greg Strauss, a Professor of Psychology and Neuroscience at University of Georgia, is a member of the Scientific Advisory Board.
Importance 40.0 Sentiment 10.0
priv
Draig Therapeutics
Draig Therapeutics is the employer of Inder Kaul, who is also on the Scientific Advisory Board of Minerva Neurosciences.
Importance 10.0 Sentiment 0.0
cnt
United Kingdom
The United Kingdom is the country where King s College London is located, an affiliation of an SAB member.
Importance 10.0 Sentiment 0.0
cnt
United States
The United States is the country where Roluperidone is being evaluated and where no therapy is currently approved for negative symptoms of schizophrenia.
Importance 10.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.